Ensuring top value of a product throughout the lifecycle process involves managing issues related to evaluating a potential product; Identifying the best people for a project, recognizing key value factors of a product, and managing the size, flow and duration of a project. This panel specifically addressed:
- How does your evaluation of a project differ in the big Pharma setting vs. a more entrepreneurial setting?
- What factors do you consider in determining whether their will be life after the patent on the active
- How have considerations changed in doing research (basic and developmental) in the last 10 years?
- What are some sources for evaluating the likelihood of success of a project?
Presenters included:
- Lisa Alexander, Corporate Patent Counsel, Novartis Institutes for Biomedical Research; Novartis Vaccines & Diagnostics
- Matt Bastardi, Vice President, Business Development & Licensing, Covidien
- James Burnes, Director, Health Care Investment Banking, Credit Suisse Securities LLC
- R. Brian McCaslin, Senior Counsel, Biotechnology & Pharmaceutical Practice, Foley
Related Insights
June 23, 2025
Labor & Employment Law Perspectives
First Circuit Concludes Employee’s Wrongful Termination, Other State Law Claims are Preempted by Federal Law
The U.S Court of Appeals for the First Circuit (covering Maine, Massachusetts, New Hampshire, Puerto Rico, and Rhode Island) recently…
June 4, 2025
Events
Selecting the Right Trustee and Role of Trust Protectors within the Trust World
June 20, 2025
Events
Wealthyist E25 | Philanthropy Trends: An Interview With Jason Kohout, Chair – Family Offices Team, Foley & Lardner
Jason Kohout, Chair of the Family Office area at Foley and Lardner and director of the Wisconsin Philanthropy Network joins Annex Private Client Wealth Strategist Brian Lamborne in episode 25 of “Wealthyist.”